Who is sponsoring NCT01400100?

NCT01400100 is sponsored by St. Josef Hospital Bochum.

What condition does NCT01400100 study?

NCT01400100 studies Pancreatic Fistula.

What drugs are being tested in NCT01400100?

Interventions: Intraarterial application of Octreotide, sterile NaCl (sodium chloride) 0,9% solution.

What is the status of NCT01400100?

NCT01400100 is currently COMPLETED.

Last reviewed 2012-03-04 · How we verify

Changes in Pancreatic Texture After Single-shot Administration of 500 µg Octreotide in the Gastroduodenal Artery During Pancreatoduodenectomy - a Double-Blinded Randomized Controlled Trial

NCT01400100 NA COMPLETED

The aim of the study is to test the hypothesis that intraarterial bolus application of 500 µg Octreotide in the gastroduodenal artery during the resectional phase of pancreatoduodenectomy in patients with soft pancreatic tissue hardens the texture of the pancreatic remnant. A primary end-point of the study is a change in pancreatic texture. A secondary end-point is the rate of postoperative pancreatic fistula.

Details

Lead sponsor	St. Josef Hospital Bochum
Phase	NA
Status	COMPLETED
Enrolment	26
Start date	2011-08
Completion	2012-03

Conditions

Pancreatic Fistula

Interventions

Intraarterial application of Octreotide
sterile NaCl (sodium chloride) 0,9% solution

Primary outcomes

Pancreatic hardness — 3 months postoperatively
Pancreatic hardness is a quantifiable parameter, measured by a Shore Durometer in Shore Units on a 0-100 SU scale.

Countries

Germany